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Polyvinyl Alcohol Embolization Adjuvant
to Oily Chemoembolization in Advanced
Hepatocellular Carcinoma with
Arterioportal Shunts
Objective: To assess the feasibility and safety of polyvinyl alcohol (PVA)
embolization adjuvant to transarterial oily chemoembolization (P-TACE) in
advanced hepatocellular carcinoma (HCC) with arterioportal shunts (APS).
Materials and Methods: Nineteen patients who underwent PVA embolization
for APS before a routine chemoembolization (TACE) procedure were retrospec-
tively reviewed. 10 of these 19 patients underwent follow-up TACE or P-TACE
after P-TACE (Group A), but nine patients underwent only initial P-TACE
because of progression of HCC and/or underlying liver cirrhosis (Group B).
Hepatic function tests, APS grades, and portal flow directions were evaluated
before and after P-TACE sessions. Complications after procedures and survival
days were also evaluated.
Results: In group A, APS grade was improved in eight patients and five of six
patients with hepatofugal flow showed restored hepatopetal flow postoperatively.
No immediate complication was developed in either group. Transient hepatic
insufficiency developed in eight (42.1%) of 19 patients after P-TACE, and seven
(87.5%) of these eight recovered within two weeks under conservative care. The
mean and median survival time all study subjects was 280 days and 162 days.
Conclusion: P-TACE is feasible and safe in advanced HCC patients with APS.
t has been reported that arterioportal shunts (APS) of the liver can be
caused by cirrhosis, metastases, hemangioma, hemangioendothelioma,
hepatic trauma, Budd-Chiari disease, or hepatocellular carcinoma (HCC)
(1). APS associated with HCC has been reported in about 28.8% to 63.2% of HCCs
(1, 2), and is considered a poor prognostic factor for following reasons. First, the shunt
flow to the portal vein aggravates the portal venous pressure, which induces life-
threatening conditions such as esophageal varix, ascites, and hepatic encephalopathy
(1, 3). Secondly, during transarterial oily chemoembolization (TACE), which has been
used for many years to treat unresectable HCC (4), oil emulsion may be diverted into
the portal vein branches and delivered to non-tumor hepatic tissue instead of being
deposited intratumorally (1), and may induce severe adverse effects such as hepatic
infarction. Therefore, we consider that APS should be managed before TACE.
A number of reports have been issued on APS embolization by coils, gelatin sponge,
a combination of coils and gelatin sponge, ethanol, and polyvinyl alcohol (PVA) (3,
5 7). Coil embolization can result in the collateralization and restoration of flow into
the vascular territory of the embolized vessels due to proximal embolization.
Additionally, when proximal occlusion occurs, repeated interventions, which are
common in HCC chemoembolization, via the same artery become difficult (8).
Moreover, gelatin sponge is absorbed completely and the embolized vessels are
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Irecanalized within a few weeks of intervention (8, 9).
Ethanol produces scarring of the bile duct, and results in
sclerosing cholangitis in an animal experimental study (10).
In contrast, PVA is not absorbable and it is more likely to
produce a permanent occlusion because of the low
frequency of recanalization. Moreover, as a particulate
embolizing agent, it is easy to handle, and is available in a
wide range of sizes (7 9). Although APS embolization
with PVA and following chemoinfusion has been
previously described (7), to the best of our knowledge, no
systemic review is available on APS embolization followed
by TACE.
We embolized APS using PVA before TACE (P-TACE)
to prevent diversion of oily emboli from the hepatic artery
to the portal vein and thus the resultant adverse effects.
This retrospective study was conducted to evaluate the
feasibility and safety of P-TACE for advanced HCC with
APS.
MATERIALS AND METHODS
Patients
Nineteen consecutive patients with unresectable HCC
and APS who underwent P-TACE were selected from
among 414 HCC patients between 1997 and 2004. The
patients with a Child-Pugh class C hepatic function, or who
underwent any treatments other than TACE throughout
the study period were excluded from the evaluation. We
obtained informed consents for about the procedures from
all the patients. These 19 patients were classified into two
groups. Group A (n = 10), patients who underwent 1 or 2
follow-up angiographies repeat TACE or P-TACE after the
initial P-TACE. During the follow-up period, both TACE
and P-TACE were performed in four patients, TACE in
five, and P-TACE in one. Group B patients (n = 9)
underwent only the initial P-TACE, because underlying
liver cirrhosis and/or HCC had progressed too far to
perform a repeated procedure or because no recurrence
was demonstrated by follow-up computed tomography
(CT).
The patient’s ages ranged from 42 to 64 in group A
(mean age: 51) and from 48 to 80 in group B (mean age:
62). Male to female ratio were 8:2 in group A and 7:2 in
group B.
Initial hepatic functions were evaluated by using the
Child-Pugh classification, and by determining serum biliru-
bin concentrations before and after P-TACE. Okuda stage,
tumor size, APS grade, presence and extent of portal vein
thrombosis, portal vein flow direction, and cavernous
transformation were also evaluated on the preprocedural
CT and angiographic images by two radiologists by
consensus (Tables 1, 2). We semi-quantitatively classified
APS from grade 0 to 3 (Table 3). 18 of the 19 patients
(95%) had tumors larger than 10 cm in maximum diameter
(Table 1). In group A, the initial APS were grade three in
nine patients and grade 2 in one patient. In group B, the
initial APS grade were grade 1 to 3 in three patients
apiece.
Intervention
Superior mesenteric arterioportography and hepatic
arteriography were performed on all patients to evaluate
portal veins and tumors. Angiograms obtained after an
iopromide injection (Ultravist 370; Schering Korea, Seoul,
Korea) were performed for superior mesenteric arteriopor-
tography at a flow rate of 4 ml/sec for 8 seconds and for
hepatic arteriography at a rate of 4 5 ml/sec for 3
seconds. P-TACE was performed in two steps. The first
step involved APS embolization with PVA (Contour;
Boston Scientific, Natick, MA). PVA particle sizes used for
the embolization were variable (150 1000  m, Table 1).
Although 355 500 and 500 710  m PVA particles were
used for APS embolization throughout the study period,
smaller particles of 150 250 and 250 355  m were used
in two patients during the early period and larger particles
(710 1000  m), alone or mixed were used in the cases
with extensive APS. When an APS had a single or two
feeders, P-TACE was selectively performed at the level of
the second or third order hepatic arteries with using a 4 Fr
catheter or a microcatheter (n = 3, Table 1). However, the
first order hepatic arteries of one or both hepatic lobes
were embolized in most of cases (Table 1). When APS
grade was converted to grade 0 by PVA embolization,
conventional TACE with oil emulsion and gelatin sponge
(Gelfoam; The Upjohn, Kalamazoo, MI) particles (size, 1
mm  1 mm  1 mm) was performed as a second step.
When parasitic blood supply was detected, the same
procedure was performed. Lobes or segments that
contained tumors without APS were treated by TACE only
(n = 2). Oil emulsions were prepared by mixing of 2 10
mg chemotherapeutic drug (Mitomycin C; Choong Wae
Pharma Corp, Seoul, Korea) and 2 20 ml iodized oil
(Lipiodol; Guerbet, Aulnay-sousBois, France) as previously
described (4). In cases with hepatofugal portal flow by
preprocedural arterioportography, portal flow was
evaluated by superior mesenteric arterioportography after
chemoembolization.
Follow-up Evaluation and Interventions
Follow-up examinations were conducted by CT with 1
3 months of initial intervention according to tumor extent
and laboratory findings. Follow-up intervention was
Kim et al.
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Fig. 1. A 43-year-old male with grade 3 arterioportal shunts and hepatocellular carcinomas (patient 4). 
A-F. Initial CT (A) revealed a large poorly enhanced mass in the left lobe of a cirrhotic liver and left portal vein thrombosis. Superior
mesenteric arterioportogram (B) showing extensive collaterals via the coronary vein and an absent main portal vein. Hepatic arteriogram
(C), showing tumor staining and extensive arterioportal shunts (black arrows) in the left hepatic lobe. The main portal vein was opacified
by hepatofugal flow. P-TACE (355-500  m, 1 bottle) was administered to the left hepatic and middle hepatic arteries. Left and middle
hepatic arteries were occluded by P-TACE (D). Follow-up superior mesenteric arterioportogram (E) obtained two months after P-TACE,
showing restored hepatopetal flow. Hepatic arteriogram (F), showing a non-opacified arterioportal shunts. performed when a tumor recurred or remained viable by
CT. When APS was severer than grade 0 was observed by
preprocedural arteriography, P-TACE was repeated and
when APS was grade 0, conventional TACE was
performed without PVA embolization.
Assessment of Feasibility
Feasibility was assessed using APS grades and the
restoration of hepatopetal flow. APS grades were assessed
on the pre- and postprocedural arteriograms of the hepatic
and/or parasitic artery. Portal venous flow direction
change was determined by superior mesenteric arteriopor-
tography before and immediately after P-TACE or TACE.
Assessment of Safety
Procedural safeties were assessed by documenting the
development of hepatic insufficiency or other complica-
tions, and by reviewing medical records, blood chemistry
results, and image findings.
Hepatic insufficiency was defined when one or both of
the following factors were positive after a procedure; a
postprocedural Child-Pugh score higher than the preproce-
dural score (2 or more), or a serum bilirubin concentration
greater than the preprocedural value (1 mg/dL or more).
We defined irreversible hepatic insufficiency as a failure to
recover blood chemistry values and clinical features within
four weeks after P-TACE and when these factors were
recovered within four weeks, we regarded the hepatic
insufficiency as transient. 
Statistical Analysis
The survival was using the Kaplan-Meier method and the
initial Okuda stages of groups A and B were compared
using Fisher’s exact test. P values of < 0.05 were consid-
ered statistically significant.
RESULTS
Assessment of Feasibility
Arterioportal shunt grades were improved in eight
(80%) patients in group A by last follow-up preprocedural
arteriography (Fig. 1, Table 1). One patient (patient 10)
with grade 3 APS failed to respond twice to P-TACE.
Another patient (patient 9) showed a transient APS
improvement from grade 3 to 0 on the preprocedural
arteriogram at the second procedure, but APS was
aggravated to grade 3 at third follow-up preprocedural
arteriography (Fig. 2).
Six (60%) patients in group A showed hepatofugal flow
on the initial preprocedural arteriograms. All of these
patients were converted to hepatopetal flow immediately
after P-TACE. On the second preprocedural arteriograms,
one patient (patient 6) had recurred partial hepatofugal
flow which was again converted to hepatopetal flow after
the second P-TACE session. This patient maintained
hepatopetal flow on the third follow-up preprocedural
arteriogram. Another patient (patient 9) whose hepatofu-
gal flow had been controlled after initial P-TACE had
recurrent hepatofugal flow on the third follow-up
procedural arteriogram. The hepatofugal flows that
recurred in these two patients were produced by recurred
APS after P-TACE (Fig. 3). Two patients (patient 4 and
15), one in each group, had no viable tumor on follow-up
CT (Table 1).
Assessment of Safety
None of the patients developed immediate complica-
tions. Postembolization syndrome manifested as fever (
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G H
Fig. 1. G, H. Follow-up CT scan (G), six months after P-TACE, showing some lipiodol retention without viable tumor. The tumor and
lipiodol retention were not observed by CT (H), 22 months after P-TACE.38 , n = 17, 68%) abdominal pain (n = 4, 16%), and
nausea (n = 4, 16%), but all of these postembolization
syndromes were controlled by analgesics and antipyretics
within a week.
Hepatic insufficiency was developed in nine (47%) of the
19 patients, eight (42.1%) after P-TACE and one (5.3%)
after TACE (Table 1). All but one of the patients recovered
within two weeks under conservative care. One patient
(patient 14) developed irreversible hepatic insufficiency
after P-TACE (Table 1). Serum bilirubin in this female
patient had been 1 mg/dL before the initial P-TACE and
subsequently increased to 5.7 mg/dL at two weeks and to
4.5 mg/dL at four weeks post P-TACE, but her
hyperbilirubinemia maintained a plateau after four weeks.
She died due to underlying HCC progression at 114 days
Kim et al.
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Fig. 3. Number of patients with hepatofugal and hepatopetal flow
in group A.
A B
C D
Fig. 2. A 51-year-old woman with grade 3 arterioportal shunt and hepatocellular carcinomas (patient 9). On initial hepatic arteriogram (A)
showing multiple tumors in both hepatic lobes (black arrows). The main portal vein (white arrow) was opacified indirectly through arterio-
portal shunt of hepatocellular carcinomas. Polyvinyl alcohol embolization was performed using half a bottle of 355 500  m sized
particles via the right hepatic artery and conventional TACE was performed in both hepatic lobes. Follow-up hepatic arteriogram (B), two
months after P-TACE, demonstrating arterioportal shunt improvement. Transarterial chemoembolization was performed without polyvinyl
alcohol embolization. After four months, arterioportal shunt recurred in both hepatic lobes with hepatofugal flow in the main portal vein
(arrow) on gastroduodenal (C) and right inferior phrenic (D) arteriograms. P-TACE was performed using one bottle of 355 500  m sized
particles into both arteries. after P-TACE.
Mean and median survivals were 400 and 256 days in
group A, and 148 and 102 days in group B, respectively.
Overall mean and median survivals were 280 and 162
days (Fig. 4). In group A, median survivals of patients that
underwent P-TACE or TACE twice (n = 5) or three times
(n = 5) were 206 and 274 days, respectively. Initial Okuda
stages were higher in group B than group A (Table 1, p <
0.05).
DISCUSSION
Recently, APS embolization has been attempted using
different embolic materials (3, 5 7). Furuse et al. (5)
performed APS embolization in 10 HCC patients without
main portal vein thrombosis using coils in combination
with gelatin sponges and achieved a median survival of 4.3
months. Tarazov et al. (6) also performed APS emboliza-
tion using coils and gelatin sponges in five patients with
HCC and APS. No serious complications were encoun-
tered in these two studies. The median survival observed
in the present study (162 days) is similar with that of
Furuse et al. (5). 95% of patients in our study had tumors
larger than 10 cm, and 47% had main portal vein
thrombosis. We attribute this relatively short survival to
advanced tumors rather than to poor response to P-TACE.
Moreover, the above studies did not provide details of
tumor volumes and main portal vein thrombosis, which
makes comparisons difficult.
Furuse et al. (5) used gelatin sponges and coils for APS
embolization and performed follow-up Doppler
ultrasonography, 1 2 weeks after embolization. They
reported APS regression and portal flow restoration after
APS embolization. However, we believe that this follow-
up period is too short to evaluate the effect of APS
embolization because gelatin sponge absorption, which
usually occurs 35 45 days after embolization (9), can
cause APS recanalization and thus portal flow reversal.
Therefore, we consider that the results by Furuse et al.
may be overestimated.
Huang et al. (3) performed ethanol embolization in HCC
patients and severe APS, and compared this with gelatin
sponge embolization. They reported a median survival of
11 months, which is much longer than the 162 days of our
study. We suppose that this survival difference reflects
tumor stage and shunt severity differences. However, no
mention was made of portal flow which would have
provided an indication of shunt severity. Moreover,
Polyvinyl Alcohol Embolization Adjuvant to Oily Chemoembolization in HCC with Arterioportal Shunt
Korean J Radiol 8(4), August 2007 317
A B
Fig. 4. Cumulative survivals of all study subjects (A) and of the two study groups (B). 
Table 2. Initial Portal Venous Flow and Portal Vein
Thrombosis
Portal Flow
PVT ( )
PVT (+)
Hepatofugal Hepatopetal MPVT (+) MPVT ( )
Group A 6  4 0 6 4
Group B 2 7 3 3 3
Note. PVT = portal vein thrombosis, MPVT = main portal vein 
thrombosis
Table 3. Definition of Arterioportal Shunt Grade
Grade Definition
0 None or limited shunt flow, less than the subsegmental 
portal vein.
1 Shunt flow regurgitated to the segmental portal vein.
2 Shunt flow regurgitated into the ipsilateral main portal 
vein of each lobe.
3 Shunt flow regurgitated into the contralateral lobe 
and/or the main portal vein.because small amounts of ethanol (2 6 ml) were used
after selecting APS feeding vessels, we believe that the
tumors were not those of advanced HCC. Because most of
our cases had large tumors, P-TACE had to be performed
at the hepatic artery proper or at first order branches.
Moreover, ethanol embolization is associated with severe
adverse effects, such as sclerosing cholangitis induced by
bile duct scarring as was reported by an experimental
study (10), although they did not encounter this complica-
tion. Another disadvantage of ethanol is that it is more
difficult to handle than particulate PVA.
There are some intrinsic reasons that favor the use of
PVA for APS embolization. PVA is not absorbable and
thus is likely to produce long-term occlusion because
recanalization is more difficult than for gelatin sponge
and/or coils (7 9). PVA particles are small as compared
with coils and gelatin sponge particles, so distal emboliza-
tion, which is mandatory to tumor embolization, is possible
(11). In addition, PVA particles are easier to handle.
In a previous study on APS embolization using PVA in
patients with HCC and portal vein thrombosis (7), 55% of
the patients showed APS improvements after first
embolization when PVA was used, which is similar to our
result (60%) after the initial P-TACE. Moreover we were
able to control APS in 80% by repeated P-TACE, when
APS remained or recurred in patients with a low risk of
hepatic failure. These results show that repeated APS
embolization using PVA is highly effective, although it
should be mentioned that two patients (20%) did not
respond to the P-TACE.
Two patients showed no viable tumor by follow-up CT.
One of these patients remains alive for 809 days after P-
TACE without evidence of tumor recurrence (Fig. 1), and
the other lived for 500 days. Although the factors that
predict response to P-TACE have not been identified, it is
evident that P-TACE can be an efficacious treatment in
some patients with APS accompanying HCC. However, P-
TACE may induce complete occlusion of tumor feeding
arteries, which reduces the amount of oil emulsion and
hence cytotoxic drug to administrated during chemoem-
bolization. We administrated oil emulsion when an APS of
grade 0 had been attained by PVA embolization. On the
follow-up CT, tumors were found to retain lipiodol, but the
amount of retention was not as great as in HCC without
APS, which means that tumor feeding vessels were not
completely occluded by PVA embolization. Therefore, we
hypothesized that APS may have been occluded earlier
than tumor feeding arteries due to high flow of the arteries
to APS.
The control of hepatofugal portal flow is vital to reduce
severe manifestations of portal hypertension and to
prevent migration of administered medication and oily
emboli via collaterals from the portal to the systemic veins
during TACE. Thus, we embolized APS with PVA before
routine TACE to prevent medications and oily emboli
from migrating into the non-targeted hepatic tissue and
systemic veins (12). In this study, although hepatofugal
flow was not amenable to P-TACE in two cases, we view
PVA embolization as a highly effective means of control-
ling hepatofugal flow associated with an APS.
In contrast to our study which involved APS emboliza-
tion and TACE, Lee et al. (7) performed APS with
chemoinfusion probably due to the concern of hepatic
insufficiency. They reported two cases of hepatic failure,
though a definition and the timings of these failures were
not mentioned. In our study, eight (42.1%) of 19 patients
manifested hepatic insufficiency by P-TACE, but only one
patient developed irreversible hepatic insufficiency despite
a relatively good preprocedural hepatic function.
However, although this patient fell into the category of
irreversible hepatic insufficiency, her hepatic failure was
not progressive. Therefore, we view that the incidence of
the post P-TACE hepatic failure (5.3%, 1/19 patients) was
low. We excluded patients with an accompanying poor
hepatic function or complete occlusion of the main portal
vein without cavernous transformation, because these
patients are apt to develop hepatic insufficiency and we
presume that this is an explanation of the low incidence of
irreversible hepatic insufficiency. In the present study, the
frequency of postembolization syndrome occurrence was
similar to those of other studies (5, 7). However, it was not
clear whether postembolization syndrome was induced by
PVA embolization or TACE.
Okuda stages of the patients were poorer in group B
than that of in group A. We believe that this led to low
survival in group B excepting the patient who survived for
500 days without additional P-TACE or TACE. Another
possible reason for the observed poor survival of group B
might have been a poor response to P-TACE. However,
we believe that the initial clinical status played a major
role in survival.
This study has some limitations. The number of the
patients enrolled was small. Follow-up periods were
relatively short as most of patients had advanced disease.
Retrospective nature prevented comparisons with other
forms of embolization or a control group. In terms of the
treatment of HCC, chemoembolization is usually not
considered for advanced tumors with APS, because non-
target embolization via APS may induce severe complica-
tions like infarction. However, the results of the present
study suggest that P-TACE can control APS safely and
effectively and demonstrate enhanced control of APS
Kim et al.
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We conclude that P-TACE appears to be a feasible and
safe means of treating APS associated with advanced
HCC.
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